

1 **Trends in antimicrobial resistance amongst *Salmonella* Typhi in Bangladesh: a 24-year**
2 **retrospective observational study (1999–2022)**

3 Arif M Tanmoy,^{1,2} Yogesh Hooda,¹ Mohammad S I Sajib,¹ Hafizur Rahman,¹ Anik Sarkar,¹
4 Dipu Das,¹ Nazrul Islam,¹ Naito Kanon,¹ Md. Asadur Rahman,³ Denise O Garrett,⁴ Hubert P
5 Endtz,² Stephen P Luby,⁵ Mohammod Shahidullah,⁶ Md. Ruhul Amin,⁷ Jahangir Alam,⁷
6 Mohammed Hanif,⁷ Samir K Saha,^{1,8} and Senjuti Saha.^{1,*}

7

8 ¹Child Health Research Foundation, Dhaka, Bangladesh.

9 ²Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, the
10 Netherlands.

11 ³Popular Diagnostic Center, Dhaka, Bangladesh.

12 ⁴Sabin Vaccine Institute, Washington, DC, USA.

13 ⁵Division of Infectious Diseases and Geographic Medicine, Stanford University School of
14 Medicine, Stanford, California, USA.

15 ⁶Department of Neonatology, Bangabandhu Sheikh Mujib Medical University, Dhaka,
16 Bangladesh.

17 ⁷Department of Pediatrics, Bangladesh Institute of Child Health, Dhaka, Bangladesh.

18 ⁸Department of Microbiology, Bangladesh Shishu Hospital and Institute, Dhaka, Bangladesh.

19

20 Short running title: *Salmonella* Typhi AMR Trends in Bangladesh (1999–2022).

21

22 **Corresponding author:* Senjuti Saha, PhD; Child Health Research Foundation, Dhaka,

23 Bangladesh. Email: senjutisaha@chrfbd.org

24

25 **Abstract**

26 **Background.** Rising antimicrobial resistance (AMR) in *Salmonella* Typhi restricts typhoid
27 treatment options, heightening concerns for pan-oral drug-resistant outbreaks. Bangladesh
28 contemplates introducing typhoid conjugate vaccine (TCV) to address the typhoid burden and
29 AMR. However, large-scale surveillance data on typhoid AMR in Bangladesh is scarce.

30 **Objective.** This study explores the AMR trends in *Salmonella* Typhi isolates from Bangladesh,
31 drawing comparisons with antibiotic consumption to optimize antibiotic stewardship strategies
32 for the country.

33 **Methods.** Our typhoid fever surveillance included two pediatric hospitals and three private
34 clinics in Dhaka, Bangladesh, spanning 1999 to 2022. Blood cultures were performed at
35 physicians' discretion; cases were confirmed by microbiological culture, serological, and
36 biochemical tests. Antimicrobial susceptibility was determined following CLSI guidelines.
37 National antibiotic consumption data for cotrimoxazole, ciprofloxacin, and azithromycin was
38 obtained from IQVIA-MIDAS database for comparison.

39 **Results.** Our 24-year surveillance, encompassing 12,435 *Salmonella* Typhi cases, revealed
40 declining trends in first-line drugs (amoxicillin, chloramphenicol, cotrimoxazole) and multidrug
41 resistance (MDR; 38% to 17%, 1999–2022). Cotrimoxazole consumption dropped, 0.8 to 0.1
42 DDD/1000/day (1999–2020). Ciprofloxacin non-susceptibility persisted (>90%) with unchanged
43 consumption (1.1-1.3 DDD/1000/day, 2002–2020). Low ceftriaxone resistance (<1%) was
44 observed, with rising MIC (0.03 to 0.12 mg/L, 1999–2019). Azithromycin consumption
45 increased (0.1 to 3.8 DDD/1000/day, 1999–2020), but resistance remained \leq 4%.

46 **Conclusion.** Our study highlights declining MDR amongst *Salmonella* Typhi in Bangladesh,
47 thus reintroducing first-line antimicrobials could work as an empirical treatment option for
48 typhoid fever. Our analysis provides a baseline for monitoring the impact of future interventions,
49 including the TCV, on typhoid burden and associated AMR.

50

51 **Introduction**

52 Antimicrobial resistance (AMR) poses a significant threat to public health, estimated to cause
53 approximately 1.27 million deaths in 2019.¹ If unchecked, deaths linked to AMR infections
54 could multiply 10-fold by 2050 due to widespread antimicrobial use and a paucity of new
55 antimicrobials.^{2,3} In response to this threat, multiple strategies have been proposed, ranging from
56 antibiotic stewardship to alternative antibiotic therapies. Implementing these interventions
57 requires guidance from surveillance data, but many low- and middle-income countries (LMICs)
58 face substantial data deficits.¹ This study aims to provide insights into AMR trends in
59 Bangladesh for *Salmonella enterica* serovar Typhi (Salmonella Typhi), the etiological agent of
60 typhoid fever, over a 24-year period, from 1999 to 2022.

61

62 Typhoid fever is a pressing global public health concern, with the majority of cases occurring in
63 South Asia.⁴ In Bangladesh, the typhoid burden is alarmingly high, especially in the capital city
64 of Dhaka, where the estimated incidence is 913 per 100,000 person-years.⁵ While the disease is
65 more prevalent among school-age children,⁶ those under 2 years old experience the highest
66 bacterial load.⁷ Clinical and epidemiological data on typhoid fever have been traditionally
67 reported from hospital-based surveillance studies, but, in many endemic countries, like
68 Bangladesh, a significant number of typhoid patients seek care at community-based diagnostic
69 centers or, hospital outpatient departments (OPD).⁸⁻¹¹ This diverse care-seeking behavior
70 complicates the precise estimation of the disease burden and AMR trends for typhoid fever.

71

72 Management of typhoid fever is becoming increasingly difficult with rising AMR. Multi-drug
73 resistant (MDR, defined as the concurrent resistance to amoxicillin, chloramphenicol, and co-
74 trimoxazole) *Salmonella* Typhi isolates emerged in the 1970s.^{12, 13} This led to ciprofloxacin as
75 the primary treatment choice by mid-1980s, but resistance followed. By mid-2010s, over 90% of
76 *Salmonella* Typhi in South Asia showed non-susceptibility to ciprofloxacin.¹⁴ The current
77 treatments include azithromycin and third-generation cephalosporins such as ceftriaxone,¹³ but,
78 reports of resistance to both drugs are increasing.¹⁵⁻²⁰ The 2016 typhoid outbreak in Pakistan,
79 caused by an extensively drug resistant (XDR; resistant to ceftriaxone, ciprofloxacin and first-
80 line of antimicrobials) lineage,¹⁹ sparked global concern. Additionally, a novel *acrB*-717 gene
81 mutation linked to azithromycin resistance,¹⁶ has narrowed treatment options and raised fears of
82 a pan-oral drug-resistant (PoDR) outbreak. A recent pan-oral resistant typhoid case has been
83 reported from Pakistan and required intravenous carbapenem and colistin treatment.²¹ This
84 highlights the looming threat of AMR and related financial burden on patients and healthcare
85 systems which is struggling to cope with high typhoid prevalence in LMICs.^{13, 22}

86
87 To curb this high burden of typhoid fever, the Government of Bangladesh is considering the
88 introduction of a typhoid conjugate vaccine (TCV). Phase-III trials have showed that the vaccine
89 reduces typhoid fever by 81–85% and it has been introduced in Pakistan, Liberia, Zimbabwe,
90 Samoa, and Nepal.^{23, 24} However, the continuous monitoring of AMR trends in the post-
91 vaccination era is essential to ensure sustained support from policymakers. This is especially
92 crucial for Bangladesh, which is poised to shed its Least-Developed Countries (LDC) status in
93 2026 and start losing financial support from Gavi for vaccines. Amidst many competing
94 priorities, policymakers of Bangladesh will require robust surveillance data to make informed
95 decisions about the TCV program. To this end, our study provides insights on the historical

96 trends in AMR through a comprehensive typhoid surveillance dataset of 12,489 *Salmonella*
97 Typhi isolates, spanning 24 years (1999-2022). It elucidates correlations between AMR and
98 antibiotic consumption, providing a baseline to guide the design of antibiotic stewardship
99 policies. It also provides insights into designing empirical treatment strategies for typhoid fever
100 management and potential strategies to combat increasing AMR in Bangladesh.

101

102 **Methods and Materials**

103 Enteric fever surveillance

104 The Child Health Research Foundation (CHRF) has been conducting enteric fever surveillance in
105 Bangladesh since 1999, with a focus on the pediatric population (<18 years of age). This
106 surveillance is carried out at three sites in Dhaka, the capital of Bangladesh with the highest
107 burden of typhoid fever.⁶ These sites are: (a) Bangladesh Shishu Hospital and Institute (BSHI), a
108 650-bed hospital that is the largest pediatric hospital in the country, (b) Dr. M R Khan Shishu
109 Hospital & Institute of Child Health (SSFH), a 250-bed hospital that is the second largest
110 pediatric hospital in Dhaka, and (c) three branches of the Popular Diagnostic Center (PDC), a
111 community-based consultation and diagnostic center. All cases were classified based on whether
112 they were treated in the outpatient facility (OPD) or admitted to the hospitals (in-patient, IPD).
113 All cases from PDC were classified as OPD. Blood samples were collected for microbiological
114 culture as a part of the diagnostic service at the attending physicians' discretion. BSHI and SSFH
115 are part of the Global Invasive Vaccine-Preventable Bacterial Disease Surveillance Network
116 since 2009.²⁵ Details of all three sites and our enteric fever surveillance program have been
117 described previously.^{8, 26} All data used in this study are given in Supplementary Data S1.

118

119 Etiological confirmation and antimicrobial susceptibility testing

120 In all hospitals, routine blood cultures were performed using standard methods, as described
121 earlier.^{8, 27} *Salmonella* Typhi isolates from PDC were reconfirmed at BSHI using biochemical
122 tests (Klingler's Iron agar, Simmons citrate agar, motility-indole, and urea agar tests) and
123 *Salmonella* agglutinating antisera (Thermo Scientific, MA, USA). Antibiotic susceptibility tests
124 were conducted for amoxicillin, cotrimoxazole, chloramphenicol, ciprofloxacin, ceftriaxone, and
125 azithromycin using the Kirby-Bauer disc diffusion method (Oxoid, Thermo Scientific, MA,
126 USA). The minimum inhibitory concentrations (MICs) for ceftriaxone and ciprofloxacin were
127 determined for two subsets of isolates (from 1999–2019 and 1999–2016 respectively), using the
128 broth microdilution method (Sigma-Aldrich, MO, USA).^{28, 29} All isolates collected before 2017
129 underwent MIC testing if recoverable on plates. Additionally, ceftriaxone MIC testing was
130 performed on a random set of isolates from the later period (2017–2019). Zone-diameters (ZD)
131 and MIC data were interpreted based on the guideline of Clinical and Laboratory Standards
132 Institute (CLSI), 2020. Azithromycin-resistant (ZD: <11 mm) and near-resistant (ZD: 11-13 mm)
133 isolates were reconfirmed using Etest strips (bioMérieux, Marcy-l'Étoile, France). The MIC₅₀ for
134 ceftriaxone and ciprofloxacin, indicating the MIC value at which 50% of tested isolates could not
135 grow, was also calculated. Ceftriaxone MIC of two isolates (MIC >256 mg/L) were excluded
136 from all related analyses, to mitigate the impact of outliers.

137

138 Acquisition and analyses of antibiotic consumption data

139 To compare the patterns of typhoid cases, we acquired antibiotic consumption data (1999-2020)
140 for co-trimoxazole, ciprofloxacin, and azithromycin from the IQVIA-Multinational Integrated

141 Data Analysis System (IQVIA-MIDAS®) database. This commercial database captures retail
142 pharmacy sales, encompassing the total antibiotic volumes sold to both retailers and hospital
143 pharmacies by wholesalers. It also records annual sales of each antimicrobial agent for each
144 country. We excluded antimicrobial sales data for the agricultural sector. Daily defined doses
145 (DDD) for these antimicrobials were gathered from ATC/DDD Index 2023
146 (https://www.whooc.no/atc_ddd_index/). DDD represents the assumed average maintenance
147 dose per day for its main indication in adults. Adjusting for population size, we calculated DDDs
148 per 1000 inhabitants per day, following the WHO's Global Antimicrobial Resistance and Use
149 Surveillance System (GLASS).³⁰ Annual population data for Bangladesh was collected from the
150 United Nations-World Population Prospect Report 2019.³¹

151

152 Statistical analysis

153 We used Pearson's correlation coefficients to assess correlations between yearly AMR patterns
154 and consumption of co-trimoxazole, ciprofloxacin, and azithromycin. All correlation tests were
155 conducted in Stata v13.0. We also examined potential non-linear resistance patterns for
156 ciprofloxacin and ceftriaxone using their MIC data, and for azithromycin with yearly resistance
157 percentage data. The analyses for ciprofloxacin and ceftriaxone employed the generalized
158 additive model (GAM) with the *mgcv* package in R (version R 4.2.3). The model formula was y
159 $\sim s(x, bs = "cs")$, with 3,214 and 3,518 observations for ciprofloxacin and ceftriaxone,
160 respectively. Yearly trend of azithromycin resistance was analyzed similarly in R (version R
161 4.2.3) using local polynomial regression.

162

163 **Results**

164 Resistance to the first-line antimicrobials amoxicillin, chloramphenicol, cotrimoxazole

165 Our typhoid fever surveillance recorded 12,435 *Salmonella* Typhi cases from 1999 to 2022 (Data
166 S1). Of these cases, 28% (3,478/12,435) required hospitalization (IPD) at either BSHI or SSFH
167 hospital (Figure S1). During this period, we observed a declining trend in resistance among
168 *Salmonella* Typhi isolates to the first-line antimicrobials—amoxicillin, chloramphenicol, and
169 cotrimoxazole. In 2002, resistance peaked at 80%, but decreased to less than 20% in recent years
170 for all three first-line antimicrobials (Figure 1a-c). This decline was also reflected in multidrug
171 resistance (MDR), which was 17% in 2022 (Figure 1d). The percentage of MDR isolates
172 remained $\leq 26\%$ since 2010 (average 20%; 18%–23% at 95% Confidence Interval, CI) and $\leq 19\%$
173 since 2017 (average 17%; 15%–19% at 95% CI).

174

175 Resistance to ciprofloxacin, ceftriaxone, and azithromycin

176 Non-susceptibility to ciprofloxacin in *Salmonella* Typhi was notably high, reaching 95% in 2001
177 from 56% in 1999, and remained above 90% throughout the study period. In 2022, 98%
178 (1,266/1,298) of the isolates were non-susceptible to ciprofloxacin (Figure 2a). We further
179 examined the non-susceptibility trend to ciprofloxacin using minimum inhibitory concentration
180 (MIC) data (Figure 3a). Our analysis with the Generalized Additive Model (GAM) of the MIC
181 data revealed a consistent trend with no significant changes in non-susceptibility to
182 ciprofloxacin. The MIC trend for ciprofloxacin remained stable at approximately 0.25 mg/L
183 throughout the entire study period (Figure 3a).

184

185 Ceftriaxone resistance, on the other hand, was rare among *Salmonella* Typhi isolates during our
186 study period. Only two isolates were ceftriaxone-resistant, one in 1999 and the other in 2000,
187 with no further instances recorded (Figure 2b). To gain detailed insights into this resistance
188 trend, we generated ceftriaxone MIC data for a subset of isolates (n = 3,518) spanning from 1999
189 to 2019. Our analysis showed a gradual increase in MIC values over time. Overall resistance to
190 ceftriaxone rose from 0.03 mg/L in 2001 to 0.12 mg/L in 2019 (Figure 3b). While these values
191 remained below the breakpoint for reduced susceptibility (1.0 mg/L as per CLSI standards, red
192 dashed line in Figure 3b), they represent a four-fold increase. A similar fourfold increase was
193 observed in the ceftriaxone MIC₅₀ during this period.

194

195 Azithromycin resistance in *Salmonella* Typhi was first identified in 2013 during our study period
196 (Figure 2c). Subsequently, an average of 2% (1%–3%; 95% CI) of *Salmonella* Typhi isolates per
197 year displayed resistance to azithromycin. An in-depth analysis using local polynomial
198 regression to examine the yearly percentage of azithromycin-resistant isolates did not show a
199 substantial increase in azithromycin resistance since its initial identification in 2013 (no data
200 shown).

201

202 Correlation between AMR and antimicrobial consumption

203 To gain deeper insights, we compared AMR data for cotrimoxazole, ciprofloxacin, and
204 azithromycin with national antimicrobial consumption data (Figure 4). Cotrimoxazole
205 consumption exhibited a notable decline, from 0.8 defined daily doses (DDD) per 1,000 persons
206 per day in 1999 to 0.1 DDD/1,000 persons/day in 2020 (Figure 4a). Concurrently, resistance to

207 cotrimoxazole showed a decreasing trend during this period (Figure 1c and 4a). Also, it showed
208 significant correlation with consumption patterns ($r = 0.77$; $p = 0.00$ at a 95% confidence
209 interval, CI).

210 Ciprofloxacin consumption remained consistent throughout the study period, between 1.1 and
211 1.6 DDD/1,000 persons/day (Figure 4b). Non-susceptibility to ciprofloxacin showed a stable
212 pattern as well, but no significant correlation with consumption was identified ($r = 0.21$; $p = 0.38$
213 at a 95% CI). On the other hand, azithromycin consumption increased by 38-fold during study
214 years, 1999-2020, from 0.1 DDD/1,000 persons/day to 3.8 DDD/1,000 persons/day. The average
215 annual increase in azithromycin consumption was 0.18 DDD/1,000 persons/day (0.07–0.29 at a
216 95% CI) (Figure 4c).

217

218 **Discussion**

219 This study provides a comprehensive analysis of 12,435 cases of typhoid fever cases spanning 24
220 years in Bangladesh, shedding light on AMR patterns of the disease. In endemic countries like
221 Bangladesh, typhoid fever is largely treated in the community settings while the hospitals deal
222 complicated cases. This unique care-seeking behavior made it challenging to estimate the true
223 typhoid burden and extent of AMR.^{10, 11} In addition, hospital-based surveillance from
224 Bangladesh reported higher proportion of MDR typhoid cases than community settings,¹⁰
225 potentially not reflecting the true scenario. To bridge this gap, we established a typhoid
226 surveillance system in Dhaka, Bangladesh, covering both hospital and community sites.^{5, 8, 32, 33}
227 Popular Diagnostic Center (PDC), the community-based site and OPD of the two study hospitals
228 contributed 72% (8,957/12,435) of the cases in our study.

229

230 We analyzed the dataset to observe trends in AMR among *Salmonella* Typhi isolates over time.
231 Notably, there were declining resistance patterns for first-line antimicrobials, including
232 amoxicillin, chloramphenicol, and cotrimoxazole (Figure 1a–c). This decline was associated with
233 a decrease in multidrug-resistant (MDR) typhoid cases (Figure 1d). Since 2017, over 80% of
234 *Salmonella* Typhi isolates have remained susceptible to first-line drugs, with the average MDR
235 rate during 2017–2022 being 17% (15%–19%, 95% CI). Similar reductions in MDR have been
236 documented in enteric fever surveillances across various countries, including India, Vietnam,
237 Laos, Indonesia, Nepal, and Pakistan (pre-2016 XDR outbreak).³⁴⁻⁴¹ The Global Typhoid
238 Genomics Consortium's report further supports decreasing MDR trends in several typhoid-
239 endemic countries including Bangladesh, India, Nepal, Indonesia, and the Philippines.⁴²
240 Additionally, our data revealed a decreasing trend in cotrimoxazole consumption, a key first-line
241 antimicrobial in Bangladesh (Figure 4a). It aligned with declining resistance to cotrimoxazole
242 over time and demonstrated a significant correlation ($r = 0.77$; $p = 0.00$ at 95% CI; Figure 1c and
243 4a). Further investigation is needed to understand the intricate relationship between drug
244 consumption and resistance.

245

246 Ciprofloxacin non-susceptibility and consumption, on the other hand, remained unchanged
247 (Figure 2a and 4b). The ciprofloxacin MIC also revealed continuing non-susceptibility (Figure
248 3a), indicating its ongoing ineffectiveness for treating typhoid in Bangladesh. The current
249 empirical typhoid treatment in the country is either ceftriaxone or oral azithromycin. Only two
250 ceftriaxone-resistant *Salmonella* Typhi isolates were identified in our study (in 1999 and 2000).
251 However, there was a gradual increase in ceftriaxone MIC from 0.03 to 0.12 mg/L over 20 years

252 (1999-2019; Figure 3b). Although still below the non-susceptibility breakpoint (1.0 mg/L as per
253 the CLSI⁴³), the ceftriaxone MIC may approach reduced susceptibility in the near future.

254

255 Azithromycin resistance in *Salmonella* Typhi was first identified in our study in 2013, but
256 remained sporadic with only 1% isolates in 2022 (Figure 2c). The consumption of the drug, on
257 the other hand increased by ~40-fold during 1999-2020 (Figure 4c). High azithromycin use may
258 exert selection pressure, potentially fostering both macrolide- and non-macrolide resistance
259 determinants in the gut.⁴⁴ The underlying molecular cause of azithromycin resistance in
260 *Salmonella* Typhi is a single-point mutation in the AcrB efflux pump gene, *acrB-717*, reported
261 globally.^{16, 42, 45} This mutation also independently emerged in diverse *Salmonella* Typhi
262 genotypes.⁴⁵ Statistical modeling of a random *Salmonella* Typhi genome dataset from
263 Bangladesh suggests a rising effective population size of azithromycin-resistant isolates.⁴⁶ Our
264 study findings do not demonstrate a similar trend (Figure 4c).

265

266 The introduction of the typhoid conjugate vaccine (TCV) in Bangladesh has the potential to
267 markedly reduce typhoid burden, including drug-resistant cases. Once introduced, the expected
268 decreasing trend in the post-TCV period will facilitate the focused effort on effective
269 antimicrobial stewardship strategies for Bangladesh. Previous studies showed that for each
270 culture-confirmed typhoid case, at least three patients receive antibiotics in Bangladesh.⁴⁷ The
271 TCV, with its decreasing trend, could significantly cut the antibiotic consumption in the country
272 which is historically high, even increasing according to our results (Figure 4b and 4c).

273

274 Before MDR typhoid spread across the globe, the first-line antimicrobials were widely used to
275 treat typhoid. These low-cost antimicrobial agents are well-tolerated and saved millions of lives
276 from typhoid fever for decades (1950s–1980s).⁴⁸⁻⁵⁰ Even countries without MDR cases, like
277 Samoa island, continue using amoxicillin as the primary typhoid treatment,^{51, 52} emphasizing the
278 efficacy of these low-cost agents. The successful use of cotrimoxazole to treat typhoid in recent
279 times, has also been reported.⁵³ All three first-line drugs have been listed as essential drugs by
280 the Government of Bangladesh since 1982, preventing pharmaceutical price hikes.⁵⁴ Unlike the
281 lengthy and expensive development of new antimicrobials, reintroducing these first-line drugs
282 for treating typhoid cases, requires no research investment. Instead, such step will provide a
283 crucial window for developing new classes of antimicrobial drugs, a process hindered by
284 significant investment barriers in the last decade.⁵⁵

285

286 However, reintroducing older drugs may raise concerns about the return of MDR with increased
287 use. The initial H58 *Salmonella* Typhi isolates in the 1990s carried MDR genes on an IncHI1
288 plasmid. Recent H58 *Salmonella* Typhi isolates in Bangladesh and other endemic countries have
289 integrated these MDR genes into a chromosomal island. This integration helps avoid plasmid-
290 imposed fitness costs, which are negative impacts on bacterial reproduction and survival due to
291 plasmid carriage.^{46, 56, 57} Due to these genomic changes, the re-emergence of MDR would require
292 this H58 lineage to become almost extinct (or at least <5%) before reconsideration. Continuous
293 clinical, laboratory, and genomic surveillance during post-TCV introduction is essential to secure
294 a safe window for the use of the first-line of antimicrobials.⁴² Monitoring antimicrobial use and
295 resistance remains crucial for successfully treating typhoid and other infections effectively.

296

297 The results of our study should be considered within the context of several limitations. First, the
298 two hospitals participating in the surveillance were among the largest pediatric reference
299 hospitals in Bangladesh, resulting in a bias towards younger patients. Second, all study sites were
300 in Dhaka, which may not represent other parts of Bangladesh. However, our data reflect the high
301 typhoid burden in the Dhaka city with a reported 57% seropositivity for typhoid fever.⁶ Third,
302 many typhoid patients in Bangladesh are empirically treated without blood culture confirmation.
303 No community-based enteric fever surveillance account for this, limiting comparisons. Finally,
304 national antibiotic consumption data from IQVIA-MIDAS® database were used in this study, as
305 regional or disease-specific data were unavailable.

306

307 Taken together, our study describes the trends in antimicrobial resistance (AMR) amongst
308 *Salmonella* Typhi isolates in Bangladesh over the last two decades, correlating them with
309 antibiotic consumption. We proposed a potential antibiotic stewardship strategy, reintroducing
310 first-line antimicrobials for treating typhoid fever. Given their >80% susceptibility for all
311 *Salmonella* Typhi isolates since 2017, this strategy could offer a viable empirical treatment
312 option. Our analysis could serve as a crucial baseline for monitoring the impact of future
313 interventions, including the TCV and improvements in water, sanitation, and hygiene (WASH),
314 on typhoid burden and AMR in the country. The upcoming years are pivotal in combatting
315 typhoid fever, and our study will be instrumental in measuring the effectiveness of interventions
316 aimed at reducing the burden and AMR of this often-neglected tropical disease.

317

318 **Acknowledgment**

319 We would like to thank all past and present members of the clinical microbiology and
320 epidemiology team of the Child Health Research Foundation.

321

322 **Funding statement**

323 The work presented here was supported by Gavi, the Vaccine Alliance, through the World
324 Health Organization-supported Invasive Bacterial Vaccine Preventable Diseases study (grant
325 numbers 201588766, 201233523, 201022732, 200749550), by leveraging the Pneumococcal
326 Vaccines Accelerated Development and Introduction Plan (PneumoADIP), by the Bill and
327 Melinda Gates Foundation through SEAP (grant number INV-008335), and by the Child Health
328 Research Foundation (CHRF).

329

330 **Ethics statement**

331 All study protocols received approval from the Ethics Review Committees (ERC) of Bangladesh
332 Shishu Hospital and Institute (BSHI). Informed written consent and clinical information were
333 obtained from parents/legal guardians for hospitalized cases. For out-patient cases, no formal
334 consent was obtained as blood samples were collected as part of routine clinical care at the
335 discretion of the treating physician and data from routine clinical care were retrospectively
336 included without identifiable information.

337

338 **Transparency declarations**

339 All authors declare no conflict of interest.

340

341 **Data Availability Statement**

342 All relevant study data are provided in the Supplementary Data S1 of the article.

343

344 **References**

- 345 1. Murray CJL, Ikuta KS, Sharara F et al. Global burden of bacterial antimicrobial resistance in
346 2019: a systematic analysis. *The Lancet* 2022; **399**: 629-55.
- 347 2. Atkins KE, Flasche S. Vaccination to reduce antimicrobial resistance. *The Lancet Global*
348 *Health* 2018; **6**: e252.
- 349 3. Baker RE, Mahmud AS, Miller IF et al. Infectious disease in an era of global change. *Nature*
350 *Reviews Microbiology* 2021.
- 351 4. Stanaway JD, Reiner RC, Blacker BF et al. The global burden of typhoid and paratyphoid
352 fevers: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Infectious*
353 *Diseases* 2019.
- 354 5. Garrett DO, Longley AT, Aiemjoy K et al. Incidence of typhoid and paratyphoid fever in
355 Bangladesh, Nepal, and Pakistan: results of the Surveillance for Enteric Fever in Asia Project.
356 *The Lancet Global Health* 2022; **10**: e978-e88.
- 357 6. Aiemjoy K, Seidman JC, Saha S et al. Estimating typhoid incidence from community-based
358 serosurveys: a multicohort study. *The Lancet Microbe* 2022.
- 359 7. Saha SK, Baqui AH, Hanif M et al. Typhoid fever in Bangladesh: implications for vaccination
360 policy. *The Pediatric infectious disease journal* 2001; **20**: 521-4.
- 361 8. Saha S, Islam M, Saha S et al. Designing Comprehensive Public Health Surveillance for
362 Enteric Fever in Endemic Countries: Importance of Including Different Healthcare Facilities.
363 *The Journal of Infectious Diseases* 2018; **218**: S227-S31.
- 364 9. Marchello CS, Birkhold M, Crump JA. Complications and mortality of typhoid fever: A
365 global systematic review and meta-analysis. *Journal of Infection* 2020; **81**: 902-10.

- 366 10. Saha S, Saha S, Ruhulamin M et al. Decreasing trend of multiresistant *Salmonella* typhi in
367 Bangladesh. *The Journal of antimicrobial chemotherapy* 1997; **39**: 554-6.
- 368 11. Saha SK, Saha SK. Antibiotic resistance of *Salmonella* typhi in Bangladesh. *Journal of*
369 *Antimicrobial Chemotherapy* 1994; **33**: 190-1.
- 370 12. Olarte J, Galindo E. *Salmonella* typhi resistant to Chloramphenicol, Ampicillin, and Other
371 Antimicrobial Agents: Strains Isolated During an Extensive Typhoid Fever Epidemic in Mexico.
372 *Antimicrobial Agents and Chemotherapy* 1973; **4**: 597-601.
- 373 13. Saha SK, Tabassum N, Saha S. Typhoid Conjugate Vaccine: An Urgent Tool to Combat
374 Typhoid and Tackle Antimicrobial Resistance. *The Journal of Infectious Diseases* 2021; **224**:
375 S788-S91.
- 376 14. Andrews JR, Qamar FN, Charles RC et al. Extensively Drug-Resistant Typhoid — Are
377 Conjugate Vaccines Arriving Just in Time? *New England Journal of Medicine* 2018; **379**: 1493-
378 5.
- 379 15. Djeghout B, Saha S, Sajib MSI et al. Ceftriaxone-resistant *Salmonella* Typhi carries an IncI1-
380 ST31 plasmid encoding CTX-M-15. *Journal of medical microbiology* 2018; **67**: 620-7.
- 381 16. Hooda Y, Sajib MS, Rahman H et al. Molecular mechanism of azithromycin resistance
382 among typhoidal *Salmonella* strains in Bangladesh identified through passive pediatric
383 surveillance. *PLoS neglected tropical diseases* 2019; **13**.
- 384 17. Jacob JJ, Pragasam AK, Vasudevan K et al. *Salmonella* Typhi acquires diverse plasmids
385 from other Enterobacteriaceae to develop cephalosporin resistance. *Genomics* 2021; **113**: 2171-6.
- 386 18. Sah R, Donovan S, Seth-Smith HMB et al. A novel lineage of ceftriaxone-resistant
387 *Salmonella* Typhi from India that is closely related to XDR S. Typhi found in Pakistan. *Clinical*
388 *Infectious Diseases* 2019.
- 389 19. Klemm EJ, Shakoor S, Page AJ et al. Emergence of an Extensively Drug-Resistant
390 *Salmonella enterica* Serovar Typhi Clone Harboring a Promiscuous Plasmid Encoding
391 Resistance to Fluoroquinolones and Third-Generation Cephalosporins. *mBio* 2018; **9**: e00105-18.
- 392 20. Wong W, Rawahi HA, Patel S et al. The first Canadian pediatric case of extensively drug-
393 resistant *Salmonella* Typhi originating from an outbreak in Pakistan and its implication for
394 empiric antimicrobial choices. *IDCases* 2019; **15**: e00492.
- 395 21. Nizamuddin S, Khan EA, Chattaway MA et al. Case of Carbapenem-Resistant *Salmonella*
396 Typhi Infection, Pakistan, 2022. *Emerging infectious diseases* 2023; **29**: 2395-7.

- 397 22. Levine MM, Simon R. The Gathering Storm: Is Untreatable Typhoid Fever on the Way?
398 *mBio* 2018; **9**: e00482-18.
- 399 23. Birkhold M, Mwisongo A, Pollard AJ et al. Typhoid Conjugate Vaccines: Advancing the
400 Research and Public Health Agendas. *The Journal of Infectious Diseases* 2021; **224**: S781-S7.
401 24. Carey ME, McCann NS, Gibani MM. Typhoid fever control in the 21st century: where are
402 we now? *Current Opinion in Infectious Diseases* 2022; **35**: 424-30.
- 403 25. Saha S, Saha SK. Invasive Bacterial Vaccine-Preventable Disease Surveillance: Successes
404 and Lessons Learned in Bangladesh for a Sustainable Path Forward. *The Journal of Infectious*
405 *Diseases* 2021; **224**: S293-S8.
- 406 26. Sajib MSI, Tanmoy AM, Hooda Y et al. Trends in antimicrobial resistance amongst
407 *Salmonella* Paratyphi A isolates in Bangladesh: 1999–2021. *PLOS Neglected Tropical Diseases*
408 2023; **17**: e0011723.
- 409 27. Saha SK, Naheed A, El Arifeen S et al. Surveillance for Invasive *Streptococcus pneumoniae*
410 Disease among Hospitalized Children in Bangladesh: Antimicrobial Susceptibility and Serotype
411 Distribution. *Clinical Infectious Diseases* 2009; **48**: S75-S81.
- 412 28. Tanmoy AM, Westeel E, De Bruyne K et al. *Salmonella enterica* serovar Typhi in
413 Bangladesh: Exploration of Genomic Diversity and Antimicrobial Resistance. *mBio* 2018; **9**.
- 414 29. Andrews JM. Determination of minimum inhibitory concentrations. *Journal of Antimicrobial*
415 *Chemotherapy* 2001; **48**: 5-16.
- 416 30. WHO. GLASS manual on the management of antimicrobial consumption data. 2020.
- 417 31. UN. World Population Prospect Report 2019. *World Population Prospects: Population*
418 *Division, Department of Economic and Social Affairs, United Nations, 2019.*
- 419 32. Saha S, Islam M, Uddin MJ et al. Integration of enteric fever surveillance into the WHO-
420 coordinated Invasive Bacterial-Vaccine Preventable Diseases (IB-VPD) platform: A low cost
421 approach to track an increasingly important disease. *PLoS neglected tropical diseases* 2017; **11**.
- 422 33. Saha S, Islam MS, Sajib MSI et al. Epidemiology of Typhoid and Paratyphoid: Implications
423 for Vaccine Policy. *Clinical Infectious Diseases* 2019; **68**: S117-S23.
- 424 34. Balaji V, Kapil A, Shastri J et al. Longitudinal Typhoid Fever Trends in India from 2000 to
425 2015. *Am J Trop Med Hyg* 2018; **99**: 34-40.
- 426 35. Nga TVT, Duy PT, Lan NPH et al. The control of typhoid fever in Vietnam. *Am J Trop Med*
427 *Hyg* 2018; **99**: 72.

- 428 36. Roberts T, Rattanavong S, Phommason K et al. Typhoid in Laos: an 18-year perspective.
429 *Am J Trop Med Hyg* 2020; **102**: 749.
- 430 37. Lugito NPH. Antimicrobial resistance of *Salmonella enterica* serovars Typhi and Paratyphi
431 isolates from a general hospital in Karawaci, Tangerang, Indonesia: A five-year review.
432 *International Journal of Microbiology* 2017; **2017**.
- 433 38. Jamilah J, Hatta M, Natzir R et al. Analysis of existence of multidrug-resistant H58 gene in
434 *Salmonella enterica* serovar Typhi isolated from typhoid fever patients in Makassar, Indonesia.
435 *New Microbes and New Infections* 2020; **38**: 100793.
- 436 39. Shrestha KL, Pant ND, Bhandari R et al. Re-emergence of the susceptibility of the
437 *Salmonella spp.* isolated from blood samples to conventional first line antibiotics. *Antimicrobial*
438 *Resistance & Infection Control* 2016; **5**: 22.
- 439 40. Khadka S, Shrestha B, Pokhrel A et al. Antimicrobial Resistance in *Salmonella* Typhi
440 Isolated From a Referral Hospital of Kathmandu, Nepal. *Microbiology Insights* 2021; **14**:
441 11786361211056350.
- 442 41. Qamar FN, Yousafzai MT, Sultana S et al. A Retrospective Study of Laboratory-Based
443 Enteric Fever Surveillance, Pakistan, 2012–2014. *The Journal of Infectious Diseases* 2018; **218**:
444 S201-S5.
- 445 42. Carey ME, Dyson ZA, Ingle DJ et al. Global diversity and antimicrobial resistance of
446 typhoid fever pathogens: Insights from a meta-analysis of 13,000 *Salmonella* Typhi genomes.
447 *eLife* 2023; **12**: e85867.
- 448 43. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI
449 supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute, 2020.
- 450 44. Doan T, Worden L, Hinterwirth A et al. Macrolide and Nonmacrolide Resistance with Mass
451 Azithromycin Distribution. *New England Journal of Medicine* 2020; **383**: 1941-50.
- 452 45. Sajib MSI, Tanmoy AM, Hooda Y et al. Tracking the Emergence of Azithromycin
453 Resistance in Multiple Genotypes of Typhoidal *Salmonella*. *mBio* 2021; **12**: e03481-20.
- 454 46. da Silva KE, Tanmoy AM, Pragasam AK et al. The international and intercontinental spread
455 and expansion of antimicrobial-resistant *Salmonella* Typhi: a genomic epidemiology study. *The*
456 *Lancet Microbe* 2022.
- 457 47. Andrews JR, Baker S, Marks F et al. Typhoid conjugate vaccines: a new tool in the fight
458 against antimicrobial resistance. *The Lancet Infectious Diseases* 2019; **19**: e26-e30.

- 459 48. Geddes AM, Murdoch JM. Ampicillin in the treatment of paratyphoid fever- a comparative
460 trial. *Postgrad Med J* 1964; **40**: 81-3.
- 461 49. Uwaydah M, Shamma'a M. The Treatment of Typhoid Fever with Ampicillin. *Lancet* 1964:
462 1242-4.
- 463 50. Gilman RH, Terminel M, Levine MM et al. Comparison of Trimethoprim-Sulfamethoxazole
464 and Amoxicillin in Therapy of Chloramphenicol-Resistant and Chloramphenicol Sensitive
465 Typhoid Fever. *Journal of Infectious Diseases* 1975; **132**: 630-6.
- 466 51. Sikorski MJ, Desai SN, Tupua S et al. Tenacious endemic typhoid fever in Samoa. *Clinical*
467 *Infectious Diseases* 2020; **71**: S120-S6.
- 468 52. Tanmoy AM. *Salmonella enterica* Serovar Typhi on an Island: No H58, No Multidrug
469 Resistance, but for How Long? *mBio* 2022; **13**: e02426-22.
- 470 53. Karki M, Pandit S, Baker S et al. Cotrimoxazole treats fluoroquinolone-resistant *Salmonella*
471 typhi H58 infection. *Case Reports* 2016; **2016**: bcr2016217223.
- 472 54. Directorate of Drug Administration. Report of the Expert Committee for Drugs on The
473 National Drug Policy of Bangladesh 1982. ed: Directorate of Drug Administration, Ministry of
474 Health & Population Control, Government of the People's Republic of Bangladesh., 1986;
475 page-7.
- 476 55. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to
477 bring a new medicine to market, 2009-2018. *Jama* 2020; **323**: 844-53.
- 478 56. Millan AS, MacLean RC. Fitness Costs of Plasmids: a Limit to Plasmid Transmission.
479 *Microbiology Spectrum* 2017; **5**: 10.1128/microbiolspec.mtbp-0016-2017.
- 480 57. Lima NCB, Tanmoy AM, Westeel E et al. Analysis of isolates from Bangladesh highlights
481 multiple ways to carry resistance genes in *Salmonella* Typhi. *BMC Genomics* 2019; **20**: 530.
482
483

484 **Figure legends**

485 **Figure 1.** Yearly trends in resistance (-R) and multidrug resistance (MDR) among *Salmonella*
486 Typhi Cases (1999-2022, Bangladesh). (a) Amoxicillin Resistance, (b) Chloramphenicol
487 Resistance, (c) Cotrimoxazole Resistance, and (d) MDR (defined as concurrent resistance to
488 amoxicillin, chloramphenicol, and cotrimoxazole). Information on MDR is presented for all
489 recorded cases.

490
491 **Figure 2.** Yearly trends in *Salmonella* Typhi susceptibility for Ciprofloxacin, Ceftriaxone, and
492 Azithromycin (1999-2022) in Bangladesh. (a) Ciprofloxacin Non-Susceptibility (NS), (b)
493 Ceftriaxone Resistance (-R), and (c) Azithromycin Resistance (-R). Susceptibility data were
494 present for 12,431, 12,414, and 8,187 cases respectively.

495
496 **Figure 3.** Changes in minimum inhibitory concentrations (MIC) for (a) ciprofloxacin and (b)
497 ceftriaxone among *Salmonella* Typhi cases from 1999 to 2022 in Bangladesh. The MICs were
498 determined for a total of 3,214 and 3,518 isolates for ciprofloxacin (1999–2016) and ceftriaxone
499 (1999–2019), respectively. The color of the dots represents resistant (red), intermediate (blue),
500 and susceptible (green) isolates. The generalized additive model (GAM) lines depict the changes
501 in the MICs (black line), with a 95% confidence interval (grey shades) over time.

502
503 **Figure 4.** Patterns of antibiotic consumption and antimicrobial resistance in (a) Cotrimoxazole,
504 (b) Ciprofloxacin, and (c) Azithromycin among *Salmonella* Typhi Cases in Bangladesh from
505 1999 to 2020. Consumption data for ciprofloxacin was unavailable from 1999 to 2001.
506 Resistance (-R) or Non-susceptibility (NS) to cotrimoxazole, ciprofloxacin, and azithromycin are

507 presented on the primary Y-axis. The secondary Y-axis displays antibiotic consumption,
508 represented as the Defined Daily Dose (DDD) per 1,000 persons per day (DDD/1,000 day/year).

509

510 **Supplementary file legends**

511 **Figure S1.** Overview of the *Salmonella* Typhi database of 12,435 cases collected from 1999–
512 2022 and MDR percentage in Bangladesh. Yearly hospitalized (IPD) and outpatient (OPD) case
513 numbers (on the left y-axis) are presented by the year of isolation. The x-axis labels indicate the
514 number of isolates collected each year. Percentages of MDR for IPD and OPD cases per year
515 represented as lines on the right y-axis.

516

517 **Data S1.** Antimicrobial resistance dataset of 12,435 typhoid cases in Bangladesh from 1999 to
518 2022 (S=Susceptible, I=Intermediate, and R=Resistant).

519







